Generic Semaglutide Set to Enter US Market

The market for GLP-1 drugs, the class of medications that includes Ozempic and Wegovy, is substantial, with the U.S. market alone valued at over $52.7 billion in 2025 and projected to grow. North America currently accounts for the vast majority of the global market share for these drugs. Without insurance, the list price for a month's supply of Wegovy is approximately $1,350, while Ozempic is around $1,028. However, manufacturer Novo Nordisk has announced it will cut these list prices to $675 per month for both drugs starting in January 2027. The introduction of generic drugs typically leads to significant price reductions. Studies have shown that prices can drop by over 50% within the first year of a generic launch. As more generic competitors enter a market, prices can eventually fall to less than 20% of the original brand-name price. While key U.S. patents on semaglutide aren't set to expire until the early 2030s, recent legal settlements could pave the way for earlier generic entry. Novo Nordisk has reached confidential settlement agreements with several generic drugmakers, including Mylan (Viatris) and Dr. Reddy's, regarding patent challenges. This follows a pattern where generic manufacturers challenge patents, often leading to settlements that allow them to launch their versions before the patent's official expiration date. A federal court has already sided with Viatris in a ruling on a specific Wegovy patent, removing one hurdle for its potential generic version. In the meantime, Novo Nordisk has been actively litigating against telehealth companies and compounding pharmacies for selling unauthorized and untested versions of semaglutide. These compounded products are not FDA-approved equivalents.